

(a) culturing the recombinant host cell of claim 34 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

36. (New) The isolated polynucleotide of claim 21 wherein said nucleic acid sequence further comprises a heterologous nucleic acid sequence.

37. (New) The isolated polynucleotide of claim 36 wherein said heterologous nucleic acid sequence encodes a heterologous polypeptide.

38. (New) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 85% identical to a sequence provided in claim 21, wherein percent identity is calculated using a CLUSTALW global sequence alignment.

A1
39. (New) The isolated polynucleotide of claim 38 wherein said nucleic acid sequence further comprises a heterologous nucleic acid sequence.

Amend
40. (New) The isolated polynucleotide of claim 39 wherein said heterologous nucleic acid sequence encodes a heterologous polypeptide.

REMARKS

In the Claims:

Claims 1- 20 have been cancelled and new claims 21-40 have been added. Support for the newly added claims may be found in the application as originally filed.

Specifically, support for new claims 21-32 may be found in Figures 3A-B, paragraph numbers 0038, 0042, 0043, 0048, 0055-0057, 0210, 0298, original claims 1, 2, 3, and 5, and throughout the application as originally filed.

Support for new claims 33-35, may be found in paragraph numbers 0017, 0018, 0099-0115, Figure 16A-D, original claims 4, 6, 17, 18, and throughout the application as originally filed.

Support for new claim 36-37, and 39-40 may be found in paragraph number 0096, and throughout the application as originally filed.


Support for new claim 38 may be found in paragraph numbers 0063, 0082, and throughout the application as originally filed.

No new matter has been added. Applicants believe that all of the pending claims before the Examiner are in condition for allowance. An early Office Action to that effect is, therefore, earnestly solicited.

If any fee is due in connection herewith not already accounted for, please charge such fee to Deposit Account No. 19-3880 of the undersigned. Furthermore, if any extension of time not already accounted for is required, such extension is hereby petitioned for, and it is requested that any fee due for said extension be charged to the above-stated Deposit Account.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: March 11, 2003